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Next-generation sequencing (NGS) has been applied successfully to the field of thera-
peutic antibody discovery, often outperforming conventional screening campaigns which 
tend to identify only the more abundant selective antibody sequences. We used NGS 
to mine the functional nanobody repertoire from a phage-displayed camelid immune 
library directed to the recepteur d’origine nantais (RON) receptor kinase. Challenges to 
this application of NGS include accurate removal of read errors, correct identification 
of related sequences, and establishing meaningful inclusion criteria for sequences-of- 
interest. To this end, a sequence identity threshold was defined to separate unrelated 
full-length sequence clusters by exploring a large diverse set of publicly available nano-
body sequences. When combined with majority-rule consensus building, applying this 
elegant clustering approach to the NGS data set revealed a wealth of >5,000-enriched 
candidate RON binders. The huge binding potential predicted by the NGS approach 
was explored through a set of randomly selected candidates: 90% were confirmed as 
RON binders, 50% of which functionally blocked RON in an ERK phosphorylation assay. 
Additional validation came from the correct prediction of all 35 RON binding nanobodies 
which were identified by a conventional screening campaign of the same immune library. 
More detailed characterization of a subset of RON binders revealed excellent functional 
potencies and a promising epitope diversity. In summary, our approach exposes the 
functional diversity and quality of the outbred camelid heavy chain-only immune response 
and confirms the power of NGS to identify large numbers of promising nanobodies.
Keywords: next-generation sequencing, clustering, nanobodies, recepteur d’origine nantais signaling, phage 
display, sequence homology, amino acid, immune repertoire diversity
INtRodUCtIoN
Nanobodies are antibody-derived therapeutic proteins based on immunoglobulin single variable 
domains (1) derived from the variable domains (VHH) of heavy chain-only antibodies that naturally 
occur in camelids (2). Conventionally, nanobodies with desired functional properties are selected 
from immune, naïve, or synthetic libraries via phage display on the antigen-of-interest (3). More 
2Deschaght et al. Mining Functional Nanobodies by NGS
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 420
recently, nanobody libraries have been explored by ribosomal, 
bacterial, or yeast surface display and by bacterial or yeast two-
hybrid selections (4–10). At the end of this selection process, 
enriched clones are screened in vitro after which hit candidates 
are identified by means of Sanger sequencing. Although this 
procedure has a proven track record, the conventional screening 
approach is often limited to throughputs of several hundreds of 
clones and thus likely represents only a fraction of the functional 
potential present in the libraries.
Next-generation sequencing (NGS) technologies have sig-
nificantly contributed to our knowledge of antibody repertoire 
diversity in different species or diseases (11–13). More so, NGS 
can be a powerful tool in the discovery process of antibody-based 
therapeutics. The large number of sequencing reads obtained by 
NGS not only enables unparalleled library quality control but 
can be applied to more completely assess the binding potential of 
antibody and nanobody repertoires (14–21). During the library 
selection process on the antigen-of-interest, the selective bind-
ers are enriched over the background of non-selective clones. A 
sequence-based frequency analysis then enables the identifica-
tion of candidate binders which are enriched on the antigen-of-
interest in comparison to a negative control condition.
Recepteur d’origine nantais (RON) is a receptor tyrosine 
kinase member of the MET proto-oncogene family (22, 23). 
RON dimerization on the cell-surface is required for activation 
after conformational changes induced by the ligand macrophage-
stimulating protein (MSP). Overexpression and splicing variants 
of RON are implicated in many processes related to cancer 
initiation, progression, and malignant conversion. Constitutive 
receptor activation triggers downstream signaling cascades criti-
cal for tumorigenesis, including RAS–MAPK and PI-3K–AKT 
pathways (24).
We used NGS to mine a camelid’s nanobody selective immune 
response to human RON (hRON) in comparison to a conven-
tional screening campaign exploring the same immune library 
for hRON-specific nanobodies. To this end, samples from phage 
display selections on hRON were sequenced by Illumina MiSeq 
(2 × 250 bp) which allows for a full coverage of the nanobody 
encoding sequences. A sequence identity-based clustering 
approach combined with majority-rule consensus building was 
utilized, which was developed using publicly available nanobody 
sequence data. This approach elegantly addressed known issues of 
PCR and sequencing errors as well as sequence diversity reduction 
and revealed a wealth of candidate hRON-binding nanobodies. 
Validation of the method came from the confirmation of all leads 
which were identified by the conventional screening campaign. In 
addition, many more functional leads were identified.
MAteRIALs ANd Methods
Proteins, Antibodies, and Cell Lines
Recombinant extracellular domain of human RON (rhRON), and 
the ligand MSP were purchased from R&D Systems (MN, USA). 
Anti-FLAG antibodies and extravidin peroxidase were purchased 
from Sigma-Aldrich (MO, USA), goat anti-mouse antibody PE 
or APC conjugated from Jackson Immuno Research (PA, USA), 
and anti-M13 monoclonal HRP Conjugate from GE Healthcare. 
HEK293T (DSMZ, Germany) and llama navel cord fibroblast 
(Llana) (Ablynx, Belgium) cell lines were transiently transfected 
using FuGENE HD (Promega, WI, USA) transfection reagent 
with full-length hRON DNA cloned into pcDNA3.1. The human 
breast cancer cell line T-47D endogenously expressing RON was 
obtained from ATCC (VA, USA).
Immunizations, Library Construction,  
and Phage display selections
Recepteur d’origine nantais-targeting nanobodies were gener-
ated through immunization of a llama with rhRON, essentially 
as described elsewhere (3). Briefly, a llama was immunized first 
with 100 µg of protein followed by three times 50 µg, after which 
blood samples were taken. Phage display libraries derived from 
peripheral blood mononuclear cells (PBMCs) were prepared 
and used as previously described (3). The VHH fragments were 
cloned into a M13 phagemid vector containing the FLAG3 and 
His6 tags. The resulting library size was 4.8 ×  108 with 91% of 
insert. The library was rescued by infecting exponentially grow-
ing Escherichia coli TG1 [(F′ traD36 proAB lacIqZ ΔM15) supE 
thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5(rK− mK−)] cells followed 
by superinfection with VCSM13 helper phage, resulting in 
4.4 × 1013 cfu/ml. For the NGS samples, the RON and the negative 
control outputs, with sizes of respectively, 8 × 106 and 9 × 105 cfu, 
were derived from one round of selection on HEK293T  cells 
expressing hRON and on HEK293T  cells, respectively. For the 
conventional screening campaign, phage display selections were 
performed on HEK239T or Llana cells expressing hRON and on 
rhRON protein either directly immobilized on plate or captured 
via biotin by streptavidin-coated magnetic beads (Dynabeads, 
Invitrogen). The phage outputs were rescued as described above 
for the library. For screening purposes, E. coli TG1 cells were 
infected with the resulting phage outputs and individual colonies 
were grown in 96-deep-well plates. The expression of monoclonal 
nanobodies was induced by addition of IPTG and the crude 
periplasmic extracts containing the nanobodies were prepared by 
freeze-thawing of the bacterial pellets overnight in PBS followed 
by centrifugation to remove cell debris.
Cloning and Production of Nanobodies
Synthetic DNA fragments (Integrated DNA Technologies, 
Belgium) encoding nanobodies from the NGS campaign and 
nanobody genes derived from the conventional screening 
approach were cloned into an expression vector in frame with 
an N-terminal OmpA signal peptide and C-terminal FLAG3 and 
His6 tags. Production and purification were in essence performed 
as described before (3).
NGs sample Preparation and sequencing
Polyclonal plasmid DNA preparations from E. coli cultures infected 
with two different phage samples (RON and negative control) 
were used as PCR template. The first PCR was performed with 
primers FR1 (5′-GAGGTGCAGCTGGTGGAGTCT-3′, encoding 
EVQLVES) and FR4 (5′-TGAGGAGACGGTGACCWGGGT-3′, 
encoding T(L/Q)VTVSS). For each sample, 48 parallel PCR 
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reactions were run with KAPA HiFi DNA polymerase (Kapa 
Biosystems) using the following protocol: 3 min at 95°C; 20 cycles 
of 20 s at 98°C, 25 s at 55°C, 10 s at 72°C; once 5 min at 72°C. After 
PCR all samples were subjected to sample clean-up (PureLink 
PCR Purification Kit, Life Technologies). In a second PCR, these 
DNA amplicons were flanked by barcoded i7 TruSeq adapters 
as prescribed (Illumina). The samples were sequenced on a MiSeq 
system using the Illumina v2 2 × 250 bp chemistry kit.
NGs data Processing
In a first step, the reads were sorted by barcode, followed by 
barcode and Illumina TruSeq adapter clipping with bcl2fastq 
1.8.4 (Illumina). Forward and reverse reads were combined using 
open source software FLASH 1.2.4 (25) available from https://ccb.
jhu.edu/software/FLASH/ (minimal overlap: 10 bases, maximum 
mismatch rate: 25%). After PCR primer sequence detection, the 
reads were turned into the forward (FR1 primer) to reverse (FR4 
primer) orientation and reads with average Phred scores <38 or 
lengths <150 bp were discarded. After translation with the freely 
available BioPhyton package1 in frame +1, starting at the 5′-end 
of the FR1 PCR primer, peptides ending in frame with the FR4 
primer sequence were considered valid, thus excluding reads with 
frameshifts and/or premature stop codons.
downloading Nanobody sequences
Publicly available nanobody sequences were downloaded from 
the NCBI Protein database2 (accessed 15 March 2016) using 
“(camelidae[Organism]) AND ((VHH) OR (Nanobody) OR (single 
domain)) AND immunoglobulin” as query. Nine hundred forty-
five matches were obtained and aligned. After visual inspection of 
this alignment, obvious non-nanobody and truncated or partial 
sequences were manually removed, leaving 888 sequences for 
clustering (Table S1 in Supplementary Material).
Nanobody Clustering and Alignment
Before clustering, the residues corresponding to IMGT V- 
DOMAIN positions 1–7 and 122–128, the first and last seven 
residues of FR1 and FR4, respectively (26), were trimmed from 
the nanobody peptide sequences. This was done in order to 
remove undesirable sequence variation introduced by the PCR 
primers used in the preparation of the NGS samples or coming 
from partial FR1 and/or FR4 regions in publicly available nano-
body sequences. The trimmed peptide sequences were clustered 
with CD-HIT version 4.6.1 (27, 28). A detailed user manual 
as well as a web server of this freely available and widely used 
clustering software package can be found at http://weizhongli-
lab.org/cd-hit/. The program was run in the slow/accurate mode 
(−g = 1), no length differences were allowed (length difference 
cutoff −s = 1), and different identity cutoffs (sequence identity 
threshold −c = 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, and 1.00) were 
evaluated.
Alignments were generated with CLC Main Workbench ver-
sion 7.6.4 (Qiagen).
1 http://biopython.org/.
2 http://www.ncbi.nlm.nih.gov/protein/.
Binding eLIsA
rhRON (1 µg/ml) was immobilized directly on 384-well microti-
ter plates. Free-binding sites were blocked by 4% Marvel in PBS. 
Next, 5 µl of crude periplasmic extracts in 50 µl 2% Marvel PBST 
were added. Nanobody binding was revealed using a mouse-
anti-FLAG HRP-conjugated antibody. The OD450nm values of each 
clone were divided by those of a negative control nanobody and 
considered positive if the resulting ratio was ≥2.
epitope Binning
Biotinylated rhRON (1 nM) was captured by NeutrAvidin immo-
bilized on 96-well microtiter plates (2 µg/ml) and blocked by 1% 
casein in PBS. Next, 1 µl of purified monoclonal phage (1011 cfu/ml) 
displaying nanobody in 100 µl, 0.1% casein PBST were added in 
the presence and absence of crude periplasmic extract contain-
ing nanobodies at 1/10 dilutions. Phage binding was detected via 
anti-M13 HRP-conjugated antibody. Competition for binding to 
an overlapping epitope was revealed by the drop in signal of phage 
binding in the presence of the nanobody in the crude periplasmic 
extract.
off-rate determination
Off-rates were determined by surface plasmon resonance of 
crude periplasmic extracts on a ProteOn instrument (Biorad, 
CA, USA). rhRON was immobilized to GLC sensor chips 
surface and nanobody binding was assessed using 1/10 diluted 
periplasmic extracts. Each nanobody was injected for 2 min at 
a flow rate of 45 µl/min to allow binding to chip-bound antigen. 
Next, binding buffer without nanobody was injected at the same 
flow rate to allow spontaneous dissociation of bound nanobody. 
Regeneration was done with 10 mM glycine HCl, pH2.5. From 
the sensorgrams obtained for the different nanobodies koff values 
were calculated. Data processing and analysis were done with 
the ProteOn Manager Software, Version 2.1.1.18 applying the 
Langmuir kinetic model.
Inhibition of MsP-Induced eRK 
Phosphorylation
Functional blockade of RON kinase activation by nanobodies 
was assessed by inhibition of ligand-induced MAPK activa-
tion in T-47D breast cancer cells. For screening purposes, the 
AlphaLISA SureFire Ultra phospho-ERK 1/2 (Thr202/Tyr204) 
kit was used (PerkinElmer, MA, USA). T-47D cells (2.0 × 104/
well in 0.1 ml) were seeded in 96-wells plates in culture medium, 
incubated for 24  h after which the medium was replaced by 
serum-free medium to synchronize the cells overnight. Cells 
were pre-incubated with nanobodies present in crude periplas-
mic extract (1/25 dilution) for 1 h, after which the RON receptor 
was stimulated by addition of 3.5 nM of MSP for 15 min at 37°C. 
The cells were resuspended in 60 µl of lysis buffer after removal 
of the medium. The amount of phosphorylated ERK versus total 
ERK was determined following the recommendations from the 
provider. Inhibition % was calculated using non-stimulated cells 
and crude periplasmic extract of irrelevant control nanobody as 
references. For IC50 determination, serum-starved T-47D cells 
(3.5  ×  104 cells/well) were incubated with serial dilutions of 
tABLe 1 | summary of next-generation sequencing raw data and initial 
processing output.
Negative 
control
Recepteur 
d’origine 
nantais
Selection output size (cfu) 9 × 105 8 × 106
Raw reads (counts) 1.0 × 107 7.5 × 106
Joined reads (counts) 4.9 × 106 3.6 × 106
Joinable fraction (%) 94 96
Full-length nanobody sequences (counts) 3.4 × 106 2.8 × 106
Unique sequences (counts) 1.8 × 106 1.1 × 106
Fraction unique sequences (%) 53 39
Unique sequences/selection output size (%) 200 14
FIGURe 1 | schematic overview of the work flows for the next-
generation sequencing and conventional screening campaigns.
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purified nanobodies (duplicates, starting at 0.6 µM) and stimu-
lated with 1 nM of MSP for 30 min at 37°C. Quantification of the 
cellular the pErk levels was done using the HTRF phospho-ERK 
(Thr202/Tyr204) Assay (Cisbio, France).
Cell Binding Assays
To screen for binding to cell-expressed RON, 1/10 diluted crude 
periplasmic extracts were incubated with HEK293T-hRON 
and HEK293T  cells (5  ×  104 cells/well) in FACS buffer (PBS 
supplemented with 10% fetal bovine serum and 0.05% sodium 
azide). Nanobody binding was detected using mouse anti-FLAG 
antibodies followed by goat anti-mouse APC conjugate. Mean 
fluorescence intensity values of each clone on the HEK293T-
hRON cells were divided by those of the background signal, 
normalized to the same ratio on HEK293T  cells. Clones were 
considered positive with a ratio ≥2. To determine EC50 values, 
a dilution series of purified nanobodies starting at 500  nM in 
duplicates was added to T-47D cells (1 × 105/well). The detection 
was carried out as described above.
Ligand Competition eLIsA
A competition ELISA was used to determine blockade of the 
binding of the MSP ligand to rhRON. rhRON (1  µg/ml) was 
immobilized directly on 96-well microtiter plates. Free-binding 
sites were blocked using 4% Marvel in PBS for 1 h at room tem-
perature. Next, a dilution series of purified nanobodies starting 
at 1 µM (in duplicate) was added simultaneously with 2 nM in-
house biotinylated MSP in 100 µl 2% Marvel PBST. MSP binding 
was detected via extravidin peroxidase.
Calculations
The sequence counts per cluster in the RON sample were multi-
plied with a factor of 1.21 (3.4 × 106/2.8 × 106) to normalize for 
the difference in total counts with the negative control sample 
(Table  1). The enrichment factor of a cluster was calculated 
as follows: number of sequences (normalized counts) in the 
RON sample belonging to that cluster divided by the number 
of sequences (counts) in the negative control sample belonging 
to the same cluster. For clusters present in the RON sample but 
not in the negative control sample, the counts in the latter were 
changed from 0 to 1 in order to calculate the enrichment factor.
Confidence intervals of proportions, EC50, and IC50 values 
were calculated with GraphPad Prism 6 (GraphPad Software).
ResULts
Next-generation sequencing was used to mine the functional 
nanobody repertoire from a camelid immune library. The experi-
ments below describe the NGS-based approach to identify RON-
selective nanobodies from an immune library in comparison with 
a conventional screening campaign (Figure 1).
NGs: Raw data Processing
A nanobody phage library was constructed from the PBMCs 
obtained from a llama immunized with rhRON. The phages were 
subjected for one selection round to HEK293T cells overexpress-
ing hRON or to the parental HEK293T cells acting as negative 
control. The nanobody sequences were PCR-amplified from the 
resulting outputs, introducing a different DNA barcode to each 
sample (negative control and RON). A total of 1.75 ×  107 raw 
reads were obtained (MiSeq Kit v2, 2 × 250 bp). After barcode 
deconvolution and clipping, 95% of the forward reads could 
be joined to their corresponding reverse reads. Translation 
of the joined DNA reads excluded 23–30% of the reads for 
further analysis caused by the introduction of frameshifts and/
or premature stop codons. These clean-up steps yielded around 
3 ×  106 full-length nanobody sequences per sample (Table  1). 
A difference between the samples was observed with respect 
to sequence diversity: the negative control sample contained 
relatively more unique sequences, compared to the RON sample 
(Table 1). Consistent with published data (14, 15), this suggests 
that the selection process enriched for RON binders, resulting in a 
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reduction of overall sequence diversity. The selection output sizes 
(Table 1) represent the maximum possible sequence diversity of 
the sequenced samples. Strong amplification of identical binders 
by the phage display process explains the 14% ratio of unique 
sequences over selection output size in the RON sample (Table 1). 
The observation that the negative control sample appears to have 
twofold (200% ratio) more unique sequences than theoretically 
possible, can be explained as follows. First, it is reasonable to 
assume a twofold error on the quantification of the selection 
output size, which was done by titrating out a phage-infected E. 
coli culture, followed by a count of colony forming units (cfu). 
Secondly, the different downstream PCR amplification steps and 
the actual MiSeq sequencing will have introduced errors resulting 
in an increased diversity.
NGs: Nanobody sequence Clustering  
and Frequency Analysis
The large number of unique sequences, >1 ×  106 per sample 
(Table 1), prompted us to first explore a meaningful reduction of 
the sequence diversity, before performing an enrichment analysis 
to identify candidate hRON binders. More so, it is well known 
that errors introduced by the different PCR and sequencing steps 
significantly hamper the correct analysis of antibody repertoire 
sequence diversity, especially for true rare clones (11). Different 
methodologies have been explored to address error reduction, 
including CDR-based clustering or clonotyping, frequency-based 
consensus building, and replicate sequencing. Clustering of related 
sequences (clonal grouping and B-cell lineage trees) has been 
used extensively in the field of antibody repertoire sequencing 
to meaningfully reduce sequence diversity (12, 13). However, the 
main challenge here is to define a sequence identity threshold that 
allows for the correct clustering of (clonally) related sequences.
To this purpose, it was decided to explore sequence diversity 
and relatedness in a large set of publicly available nanobody 
sequences. Nanobody sequences were downloaded, curated (see 
Materials and Methods) and the 888 sequences thus obtained 
were further reduced to a non-redundant set of 629 unique nano-
bodies. Sequence clustering was done using CD-HIT (27, 28), 
a freely available program to efficiently handle extremely large 
datasets. Briefly, the algorithm sorts input sequences from long 
to short and processes them sequentially. The first sequence is 
classified as the first cluster representative, after which each of 
the remaining sequences is compared to the representative 
sequences found before it and classified as redundant or repre-
sentative based on similarity. The public dataset was clustered at 
sequence identity thresholds ranging from 0.7 (70% identity) to 
1.0 (100% identity) with no length differences being allowed. For 
each of the resulting clusters, we checked whether its members 
were related nanobodies or not. The term related as used here, 
refers to either targeting the same antigen, originating from the 
same publication, or sharing a database submission origin (date 
and authors). Lowering sequence identity thresholds lead to a 
continuous increase in cluster size (number of sequences per 
cluster), in number of clusters containing unrelated nanobody 
sequences, and in number of unrelated nanobody sequences 
per cluster (Figure 2; Table S1 in Supplementary Material). To 
illustrate this trend better, sequence alignments were generated 
(Figure S1 in Supplementary Material) with the members of a few 
representative clusters, identified by capital letters in Figure 2. The 
sequences captured by clusters A, B, and C, respectively, target 
the same antigen and thus are deemed related. On the other hand, 
most of the sequences captured by clusters D, E, and F target dif-
ferent antigens and thus are qualified as unrelated. Based on these 
findings, it was decided to apply an identity threshold of 0.9 for the 
further analysis of the NGS data set.
Similar to the observation with the clusters of unique (100% 
identical) sequences (Table 1), the negative control sample had 
more clusters with a sequence identity threshold of 0.9 than the 
RON sample (Table  2). The threefold reduction in number of 
clusters in the RON sample compared to the negative control 
sample indicates a decrease in sequence diversity driven by the 
positive selection pressure. Clusters were subdivided in three 
groups, based on size: orphan clusters have one single member, 
medium clusters contain 2–10 members, and large clusters 
contain >10 members. After selection on the antigen, a reduction 
in number of orphan and medium clusters was observed also here, 
while the number of large clusters increased (Table 2), sugges-
tive of positive selection pressure for clusters of hRON-binding 
sequences. Accordingly, the fraction of sequences present in large 
clusters and the mean cluster sizes increased after the selection on 
hRON (Table 2).
Besides cluster size, also the enrichment factor (ratio of 
sequence counts per cluster in RON sample over negative control 
sample) can be considered as a meaningful parameter to select 
candidate RON-specific nanobodies. To add more statistical 
robustness to our analysis, only clusters with a size ≥10 and an 
enrichment factor ≥10 were considered. These inclusion criteria 
resulted in a >50-fold reduction in the number of clusters from 
2.7 × 105 to 5,173 (Table 2; Figure 3). The resulting large panel 
of 5,173 clusters with a sequence identity threshold of 0.9—all 
different candidate hRON binders—has enrichment factors of up 
to 3,000 and cluster sizes of up to 2.7 × 105 counts (Figure 3).
Binding and Functional Characterization 
of RoN Nanobodies
In the conventional screening campaign, the same immune phage 
library was selected for up to two rounds on cells overexpressing 
hRON and/or on rhRON. Crude periplasmic extracts of enriched 
single clones were evaluated for binding by ELISA and FACS, fol-
lowed by Sanger sequencing of the hits (Table S2 in Supplementary 
Material; blue squares in Figure 4A). Sequence analysis revealed 
that all 35 nanobodies derived from the conventional screening 
were correctly identified by the NGS approach (blue squares in 
Figure 3) with enrichment factors ranging from 13 to 1,364 and 
cluster sizes ranging from as low as 16 to as high as 2.7 × 105 counts 
(Table S2 in Supplementary Material). The conventional screen-
ing approach tended to identify the most abundant sequences: 
17 out of 22 clusters (77%) with a cluster size >1.0 × 104 counts 
were also found via the conventional screening. However, small 
clusters with relatively small enrichment factors were also identi-
fied by the conventional approach (see blue squares in bottom 
left quadrant of Figure  3). The fact that all 35 conventionally 
identified nanobodies were captured by the 5,173 NGS clusters 
validates our frequency-based CD-HIT clustering NGS approach 
FIGURe 3 | Next-generation sequencing (NGs) frequency analysis 
identifies 5,173 candidate human RoN binders. All symbols represent 
CD-HIT clusters (0.9 sequence identity threshold) with cluster sizes 
[sequence counts in the recepteur d’origine nantais (RON) sample] ≥10 and 
enrichment factors (ratio of sequence counts per cluster in RON sample over 
negative control sample) ≥10. Blue squares represent the clusters that were 
also identified by the conventional screening campaign. Green triangles 
represent the NGS clusters that were selected for further screening. Clusters 
for which no sequence counts were observed in the negative control sample 
were attributed a sequence count of one, in order to be able to calculate and 
plot enrichment factors for these clusters.
tABLe 2 | summary of next-generation sequencing Cd-hIt 0.9 clusters.
Negative 
control
Recepteur 
d’origine 
nantais
All clusters (count) 8.1 × 105 2.7 × 105
Mean cluster size (# sequences) 4 11
Orphan clusters (1 member) (count) 6.5 × 105 1.9 × 105
Fraction of total sequences (%) 19 7
Medium clusters (1 < n ≤ 10 members) (count) 1.3 × 105 6.5 × 104
Fraction of total sequences (%) 14 8
Mean cluster size (# sequences) 3.8 3.4
Large clusters (n > 10 members) (count) 3.1 × 104 1.2 × 104
Fraction of total sequences (%) 67 86
Mean cluster size (# sequences) 75 208
FIGURe 2 | Clustering of publicly available nanobody sequences. On the x-axis, the different CD-HIT clustering exercises at various sequence identity 
thresholds are shown, including the number of clusters at a given threshold. The y-axis (cluster size) displays the sequence counts per cluster. The symbol size 
indicates the number of unrelated nanobody sequences. The identities of the sequences in each cluster are given in Table S1 in Supplementary Material. The 
alignments of the sequences captured in clusters identified by a capital letter are shown in Figure S1 in Supplementary Material.
6
Deschaght et al. Mining Functional Nanobodies by NGS
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 420
as an efficient method to identify binders. At the same time, it 
emphasizes the huge binding potential of the immune library 
that is left untapped by the conventional approach, which in this 
particular case means that the RON library could theoretically 
contain >100 times more binders.
To explore the untapped binding potential predicted by the 
NGS analysis, 28 additional clusters were randomly selected for 
evaluation in hRON-binding ELISA and FACS. The selected 
clusters represent a range of enrichment factors from 13 to 406 
and cluster sizes from 309 to 1.4 × 104 counts (Table S2 in Supple-
mentary Material; green triangles in Figure 3). The majority-rule 
FIGURe 4 | (A) Binding to human RON (hRON) of candidate binders. Shown 
are the selective binding ratios of ELISA and FACS experiments. (B) Inhibition 
of ligand-induced ERK phosphorylation by candidate binders. Shown are the 
% inhibition of ERK phosphorylation and the selective binding ratios of the 
ELISA experiment. Green triangles represent 28 randomly selected candidate 
hRON-binding nanobodies, predicted by the next-generation sequencing 
(NGS) analysis. Blue squares represent 35 hRON-binding nanobodies, 
predicted by the NGS analysis and identified in the conventional screening 
campaign. The white triangle represents nanobody NGS00009 which was 
not analyzed in the FACS experiment (see Table S2 in Supplementary 
Material) and as such was given a selective binding ratio of 0, but scored 
positive in the ELISA and pERK assays.
FIGURe 5 | Absence of correlation between next-generation 
sequencing cluster size or enrichment factor and binding strength to 
recepteur d’origine nantais (RoN). Shown are selective binding ratios 
from the ELISA experiment of each candidate human RON-binding nanobody 
and the (A) size (sequence counts in the RON sample) or (B) enrichment 
factor (ratio of sequence counts per cluster in RON sample over negative 
control sample) of the corresponding clusters.
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consensus, derived from the alignment of all the sequences that 
make up a given cluster, was then used as the sequence repre-
sentative of that cluster. In this manner, the sequence information 
of the most abundantly present (enriched) sequences in a given 
cluster is efficiently captured while at the same time PCR and 
read errors are filtered out (11). The consensus sequences were 
reverse translated, ordered as synthetic DNA, and cloned into an 
E. coli expression vector. Crude periplasmic extracts of each clone 
were used to assess binding to hRON in ELISA and FACS. Of 
these randomly selected NGS nanobodies, 25/28 (89%, with 95% 
confidence interval of 72–98%) bind to hRON with comparable 
binding levels to the clones also identified by the conventional 
campaign (Table S2 in Supplementary Material; compare green 
triangles to blue squares in Figure 4A). Moreover, 14/25 (56%, 
with 95% confidence interval of 35–76%) of the randomly 
selected binders show functional blockade in the MSP-induced 
ERK phosphorylation assay (Figure 4B).
An interesting observation is that there is no clear correlation 
between the binding strength of a given cluster—as measured 
by its ELISA ratio to rhRON—and its size or enrichment factor 
(Figure 5). In other words, it is probably ill-advised to overly focus 
on cluster size or enrichment factor as sole inclusion criteria for 
candidate binders. Good binders can be found in any quadrant of 
Figure 3. Extrapolating from the data of the 28 randomly selected 
clusters, we speculate that around 90% of the >5,000 remaining 
unexplored clusters could constitute RON binders, of which more 
than half could interfere with RON function.
Twelve hRON-binding nanobodies identified by both the 
NGS and conventional approaches were further characterized as 
pur ified protein. Binding affinities were assessed on T-47D cells 
endogenously expressing RON, indicating EC50 values ranging 
from >1 μM to 50 pM, and with off-rates ranging from 7 × 10−3 
to 3 × 10-4 s−1 (Table 3). More so, all nanobodies completely inhib-
ited MSP-induced ERK phosphorylation in T-47D cells with IC50 
values ranging from 300 to 5 nM (Table 3; Figure 6). Nine out of 
twelve fully block the binding of the MSP ligand to hRON, three 
others are competing only poorly—if at all—with MSP binding in 
the tested concentration range (Table 3; Figure 6). Competition 
experiments revealed that the nanobodies could be assigned to 
four non-overlapping epitope bins. Two of the nanobodies share 
a competing footprint with two epitope bins. Together these data 
indicate that functionally inhibiting anti-hRON nanobodies 
are present in the immune repertoire with good potencies and 
epitope diversity.
tABLe 3 | overview characterization of selected anti-human RoN nanobodies.
Id koff (s−1) eC50 (M) binding IC50 (M) inhibition of MsP bindinga IC50 (M) inhibition of eRK phosphorylationa epitope bin
8A09 6.2 × 10−4 9.3 × 10−11 1.6 × 10−8 (98%) 4.9 × 10−9 (100%) A
8F09 6.4 × 10−4 2.0 × 10−10 1.2 × 10−8 (98%) 5.2 × 10−9 (99%) A
11F05 4.6 × 10−4 5.3 × 10−11 9.7 × 10−9 (98%) 6.0 × 10−9 (100%) A
8A12 2.8 × 10−3 1.2 × 10−10 7.0 × 10−9 (96%) 1.3 × 10−8 (100%) C–D
8D12 5.1 × 10−4 6.1 × 10−11 1.1 × 10−8 (98%) 1.5 × 10−8 (100%) A
8C09 2.3 × 10−3 1.7 × 10−7 4.7 × 10−8 (90%) 3.3 × 10−8 (100%) A
8G11 9.7 × 10−4 3.4 × 10−8 2.4 × 10−7 (92%) 8.2 × 10−8 (98%) B
5C06 3.7 × 10−3 2.0 × 10−7 2.2 × 10−8 (98%) 1.2 × 10−7 (98%) A
2C06 6.9 × 10−3 >1.0 × 10−6 2.5 × 10−7 (90%) 3.0 × 10−7 (92%) A
5G04 2.9 × 10−4 3.3 × 10−10 n.a. (92%) 4.9 × 10−9 (100%) C–D
2D07 5.0 × 10−3 5.0 × 10−9 n.a. (30%) 1.8 × 10−8 (100%) D
2B09 1.8 × 10−3 1.3 × 10−9 n.a. (67%) 9.6 × 10−8 (96%) C
aEfficacy or maximum inhibition is shown between parentheses.
n.a.: IC50 values could not be determined due to incomplete dose–responses in the range of concentrations tested. The reported inhibition corresponds to the % inhibition observed 
at 1 µM of 2D07 and 2 µM of 5G04 and 2B09.
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sequence diversity of RoN Nanobodies
Sequence analysis of the 28 randomly selected nanobodies and 
the 35 nanobodies identified by both conventional and NGS 
campaigns revealed an extensive functional sequence diversity 
(Figure 7). This is best illustrated by the observation that most 
nanobodies have very different CDR sequences. Together, these 
results confirm that our NGS-based approach is able to cor-
rectly predict large numbers of unrelated functional nanobody 
sequences targeting the same antigen and illustrate the functional 
diversity and quality of the outbred camelid’s heavy chain-only 
immune response.
dIsCUssIoN
A classic difficulty in the field of antibody repertoire sequencing 
is the clustering of clonally related sequences derived from the 
same progenitor during B cell maturation (12, 13). While NGS 
analysis for antibody-derived binders such as scFvs and Fabs 
often is limited to the CDR3 region, the short length of nano-
bodies brings the advantage to obtain high quality full-length 
coverage by pairing of forward and reverse reads obtained with 
Illumina 2 × 250 bp chemistry, as demonstrated before (17–21). 
As a consequence, the downstream data analysis can reliably 
make use of all the FR and CDR sequence information. Without 
experimental data to support relatedness of antibody sequences 
at the phenotypic level, selecting a sequence identity threshold 
for clustering is relatively arbitrary. Here, we applied an inverse 
approach to the problem: rather than defining relatedness, we 
sought to define unrelatedness. Using a large set of publicly 
available nanobody sequences, we explored a range of sequence 
identity thresholds. The diverse nature of this data set makes it a 
highly representative source to sample unrelatedness. Clustering 
of unrelated nanobody sequences became apparent at sequence 
identity thresholds of 80% and lower. We selected a threshold 
of 90% to cluster the NGS dataset and subsequently obtained 
a high degree of experimental validation for these clusters. 
Other sequence identity thresholds could of course be explored, 
FIGURe 6 | dose–response curves of selected anti-human RoN 
(hRoN) nanobodies inhibiting ligand-induced eRK phosphorylation 
(A) and binding of ligand to hRoN (B). Symbol colors relate to the different 
epitope bins to which the nanobodies belong (table 3): bin A (shades of 
blue), bin B (purple), bin C (green), bin D (red), and bin C–D (shades of 
orange).
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involving a tradeoff between the number of candidate clusters 
and their relative correctness. An increased stringency results in 
a larger number of clusters containing fewer unrelated sequences, 
whereas a lower stringency results in fewer clusters to choose 
from, with a higher proportion of unrelated sequences. The con-
cept of using the diversity of publicly available data to establish 
meaningful sequence identity thresholds for clustering of related 
sequences is applicable to other types of antibody-derived bind-
ing domains and simple binding scaffolds.
The major challenge was the choice of inclusion criteria to rep-
resentatively sample such a large diversity of candidate binders. 
One way to reduce the number of candidate binders is to apply 
more stringent cutoff values to cluster size and enrichment factor. 
However, this creates a bias toward the more abundant binders 
which are also identified by the conventional screening approach, 
as shown here. More so, we did not observe a clear correlation 
between the binding properties of a given cluster and its size or 
enrichment factor. In other words, good binders can be found 
among the more abundant and enriched clusters as well as among 
the less frequent clusters. Alternatively, lowering the sequence 
identity threshold for clustering would result in a lower number of 
clusters to sample from. However, as discussed above, this would 
increase the likelihood of clustering unrelated sequences, result-
ing in a higher proportion of erratic majority-rule consensuses 
as representatives. By random sampling representatively across a 
wide range of cluster sizes and enrichment factors, we achieved 
FIGURe 7 | Alignment of human RoN (hRoN) nanobodies (see also table s2 in supplementary Material). The 28 randomly selected candidate hRON-
binding nanobodies are identified by the acronym “NGS” followed by a five digit number. The three sequences marked by an asterisk (NGS00003, NGS00020, and 
NGS00027) are the non-binding sequences from the randomly selected panel of 28. The 35 nanobodies discovered in the conventional screening campaign and 
predicted by the next-generation sequencing (NGS) analysis are identified by a one or two digit number, followed by a letter, followed by a two digit number. 
Numbering of alignment positions was done according to the IMGT V-DOMAIN system (26). CDR regions are highlighted in gray. Dots represent residues identical  
to the top sequence. Dashes represent gaps introduced by the alignment.
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